Xylyx Bio

Xylyx Bio is a private, pre-revenue biotech company developing a novel solution to the global organ shortage crisis through its proprietary XC™ Platform. The platform utilizes xenogeneic cross-circulation with a porcine bioreactor to rehabilitate and bioengineer discarded human donor organs into functional whole organ grafts, branded as Inspirex™. Its pipeline includes lung, liver, kidney, and heart graft programs, with the lung and liver in preclinical stages and the kidney and heart in prototype development. The company is supported by foundation grants and is focused on advancing its lead programs toward clinical trials.

XC™ Platform: A xenogeneic cross-circulation system that uses a living, genetically engineered porcine bioreactor to provide normothermic, systemic physiological support to rehabilitate and bioengineer discarded human donor organs into functional whole organ grafts (Inspirex™).

Xylyx Bio competes in the broader organ replacement field, which includes traditional donor transplants, xenotransplantation companies (e.g., United Therapeutics, eGenesis), and tissue engineering firms using decellularization/recellularization or 3D bioprinting. Its unique approach of rehabilitating human organs via cross-circulation differentiates it from these strategies.